文献速递哮喘

贝那利珠单抗治疗过敏性哮喘的随机双盲安慰剂对照试验

Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Eur Respir J · 2024-09-12

该随机双盲安慰剂对照试验纳入46例过敏性哮喘患者,每4周给予贝那利珠单抗30 mg或安慰剂共8周(3剂)。贝那利珠单抗显著减少血、痰和骨髓嗜酸性粒细胞,但未显著改变过敏原诱导的迟发哮喘反应(LAR),提示嗜酸性粒细胞减少 alone 不足以抑制LAR。

要点

  • 贝那利珠单抗8周治疗显著降低血、痰和骨髓嗜酸性粒细胞。
  • 贝那利珠单抗未显著改善过敏原诱导的迟发哮喘反应(LAR)。
  • 贝那利珠单抗组不良事件报告率低于安慰剂组(30.4% vs 60.9%)。

核心结论

  • 贝那利珠单抗8周治疗显著减轻过敏性哮喘患者的血、骨髓和痰嗜酸性粒细胞增多,但未改变迟发哮喘反应,提示嗜酸性粒细胞单独并非过敏原诱导支气管收缩的关键组分。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,46例过敏性哮喘患者随机接受贝那利珠单抗30 mg(n=23)或匹配安慰剂(n=23),每4周一次共8周(3剂),第9周和第12周进行过敏原激发。

主要发现

  • 贝那利珠单抗组较安慰剂组在治疗开始后4周血嗜酸性粒细胞显著减少,9周时痰和骨髓嗜酸性粒细胞显著减少。
  • 第9周过敏原激发后7小时,贝那利珠单抗组痰嗜酸性粒细胞增多较安慰剂组显著减弱(最小二乘均值差-5.81%,95%CI -10.69至-0.94%;p=0.021)。
  • 迟发哮喘反应(LAR)在两组间无显著差异(最小二乘均值差2.54%,95%CI 3.05至8.12%;p=0.363)。
  • 不良事件报告:贝那利珠单抗组7例(30.4%),安慰剂组14例(60.9%)。

临床怎么用

  • 对于过敏性哮喘患者,贝那利珠单抗可显著降低组织及血液嗜酸性粒细胞,但不应仅以抑制LAR为治疗目标。

局限性

  • 研究纳入的是轻度过敏性哮喘患者,结论外推至中重度哮喘需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Benralizumab induces rapid and near-complete depletion of eosinophils from blood and lung tissue. We investigated whether benralizumab could attenuate the allergen-induced late asthmatic response (LAR) in participants with allergic asthma. METHODS: Participants with allergic asthma who demonstrated increased sputum eosinophils and LAR at screening were randomised to benralizumab 30 mg or matched placebo given every 4 weeks for 8 weeks (3 doses). Allergen challenges were performed at weeks 9 and 12 when blood, sputum, bone marrow and bronchial tissue eosinophils and LAR were assessed. RESULTS: 46 participants (mean age 30.9 years) were randomised to benralizumab (n=23) or placebo (n=23). Eosinophils were significantly reduced in the benralizumab group compared with placebo in blood at 4 weeks and sputum and bone marrow at 9 weeks after treatment initiation. At 7 h after an allergen challenge at week 9, sputum eosinophilia was significantly attenuated in the benralizumab group compared to placebo (least squares mean difference -5.81%, 95% CI -10.69- -0.94%; p=0.021); however, the LAR was not significantly different (least squares mean difference 2.54%, 95% CI 3.05-8.12%; p=0.363). Adverse events were reported for seven (30.4%) and 14 (60.9%) participants in the benralizumab and placebo groups, respectively. CONCLUSION: Benralizumab administration over 8 weeks resulted in a significant attenuation of blood, bone marrow and sputum eosinophilia in participants with mild allergic asthma; however, there was no change in the LAR, suggesting that eosinophils alone are not a key component of allergen-induced bronchoconstriction.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Gauvreau GM, Sehmi R, FitzGerald JM, et al. Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial. Eur Respir J. 2024. PMID: 39060015. doi:10.1183/13993003.00512-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。